{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:40Z","timestamp":1789427320488,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02475-6","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:01:50Z","timestamp":1723640510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cancer\/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Sukumar","family":"Kalvapudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil Goud","family":"Pachimatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Seager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarabjot","family":"Pabla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"9","key":"2475_CR1","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/jcm9093049","volume":"9","author":"V Gambardella","year":"2020","unstructured":"Gambardella V, et al. Precision medicine to treat advanced gastroesophageal adenocarcinoma: a work in progress. J Clin Med. 2020;9(9):3049.","journal-title":"J Clin Med"},{"issue":"15","key":"2475_CR2","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","volume":"49","author":"U Ronellenfitsch","year":"2013","unstructured":"Ronellenfitsch U, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3149\u201358.","journal-title":"Eur J Cancer"},{"key":"2475_CR3","doi-asserted-by":"publisher","first-page":"175883592311731","DOI":"10.1177\/17588359231173177","volume":"15","author":"A Petrillo","year":"2023","unstructured":"Petrillo A, Smyth EC, van Laarhoven HWM. Emerging targets in gastroesophageal adenocarcinoma: what the future looks like. Ther Adv Med Oncol. 2023;15:17588359231173176.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"2475_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/CCO.0000000000000630","volume":"32","author":"A Petrillo","year":"2020","unstructured":"Petrillo A, Smyth EC. Multimodality treatment for localized gastric cancer: state of the art and new insights. Curr Opin Oncol. 2020;32(4):347\u201355.","journal-title":"Curr Opin Oncol"},{"key":"2475_CR5","unstructured":"Key Statistics About Stomach Cancer. 2023 https:\/\/www.cancer.org\/cancer\/types\/stomach-cancer\/about\/key-statistics.html.Accessed 12 Dec 2023"},{"key":"2475_CR6","unstructured":"Key Statistics for Esophageal Cancer. 2023 https:\/\/www.cancer.org\/cancer\/types\/esophagus-cancer\/about\/key-statistics.html.Accessed 12 Dec 2023"},{"key":"2475_CR7","unstructured":"Yoon, H.H. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer. 2023 https:\/\/www.uptodate.com\/contents\/initial-systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer?search=gastroesophageal%20adenocarcinoma&source=search_result&selectedTitle=2~52&usage_type=default&display_rank=2. Accessed 12 Dec 2023"},{"issue":"4","key":"2475_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"key":"2475_CR9","doi-asserted-by":"publisher","first-page":"188558","DOI":"10.1016\/j.bbcan.2021.188558","volume":"1","author":"P Yang","year":"2021","unstructured":"Yang P, Meng M, Zhou Q. Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochimica et Biophysica Acta (BBA)\u2014Rev Cancer. 2021;1:188558.","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Rev Cancer"},{"key":"2475_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107889","volume":"98","author":"X Meng","year":"2021","unstructured":"Meng X, et al. A novel era of cancer\/testis antigen in cancer immunotherapy. Int Immunopharmacol. 2021;98: 107889.","journal-title":"Int Immunopharmacol"},{"key":"2475_CR11","doi-asserted-by":"publisher","first-page":"1190883","DOI":"10.3389\/fimmu.2023.1190883","volume":"14","author":"H Ai","year":"2023","unstructured":"Ai H, et al. Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers. Front Immunol. 2023;14:1190883.","journal-title":"Front Immunol"},{"key":"2475_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-pharmtox-011112-140326","volume":"54","author":"AW Whitehurst","year":"2014","unstructured":"Whitehurst AW. Cause and consequence of cancer\/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 2014;54:251\u201372.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"2475_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","volume":"4","author":"ZA Gibbs","year":"2018","unstructured":"Gibbs ZA, Whitehurst AW. Emerging contributions of cancer\/testis antigens to neoplastic behaviors. Trends in cancer. 2018;4(10):701\u201312.","journal-title":"Trends in cancer"},{"issue":"54","key":"2475_CR14","doi-asserted-by":"publisher","first-page":"92966","DOI":"10.18632\/oncotarget.21715","volume":"8","author":"VL da Silva","year":"2017","unstructured":"da Silva VL, et al. Genome-wide identification of cancer\/testis genes and their association with prognosis in a pan-cancer analysis. Oncotarget. 2017;8(54):92966.","journal-title":"Oncotarget"},{"issue":"1","key":"2475_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2867-5-4","volume":"5","author":"M Kalejs","year":"2005","unstructured":"Kalejs M, Erenpreisa J. Cancer\/testis antigens and gametogenesis: a review and \u201cbrain-storming\u201d session. Cancer Cell Int. 2005;5(1):4.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"2475_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","volume":"5","author":"E Fratta","year":"2011","unstructured":"Fratta E, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164\u201382.","journal-title":"Mol Oncol"},{"key":"2475_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S35570","volume":"2","author":"DK Krishnadas","year":"2013","unstructured":"Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. ImmunoTargets Ther. 2013;2:11\u20139.","journal-title":"ImmunoTargets Ther"},{"issue":"1","key":"2475_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512329","volume":"8","author":"JG Pol","year":"2019","unstructured":"Pol JG, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1): e1512329.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2475_CR19","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","volume":"12","author":"C Barrow","year":"2006","unstructured":"Barrow C, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006;12(3):764\u201371.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2475_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/bjc.2013.51","volume":"108","author":"S Fujiwara","year":"2013","unstructured":"Fujiwara S, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108(5):1119\u201325.","journal-title":"Br J Cancer"},{"issue":"1","key":"2475_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ags3.12406","volume":"5","author":"Y Imamura","year":"2021","unstructured":"Imamura Y, et al. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg. 2021;5(1):46\u201359.","journal-title":"Ann Gastroenterol Surg"},{"issue":"10294","key":"2475_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"key":"2475_CR23","first-page":"VII","volume":"182","author":"PM Schneider","year":"2010","unstructured":"Schneider PM. The siewert lesson for adenocarcinomas of the esophagogastric junction: a plea for an order in a complex disease. Recent Results Cancer Res. 2010;182:VII\u2013VIII.","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"2475_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","volume":"20","author":"JM Conroy","year":"2018","unstructured":"Conroy JM, et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J Mol Diagn. 2018;20(1):95\u2013109.","journal-title":"J Mol Diagn"},{"issue":"12","key":"2475_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260089","volume":"16","author":"JM Conroy","year":"2021","unstructured":"Conroy JM, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE. 2021;16(12): e0260089.","journal-title":"PLoS ONE"},{"issue":"11","key":"2475_CR26","first-page":"1129","volume":"21","author":"TMJ Fruchterman","year":"1991","unstructured":"Fruchterman TMJ, Reingold EM. Graph drawing by force-directed placement. Soft: Pract Exp. 1991;21(11):1129\u201364.","journal-title":"Soft: Pract Exp"},{"issue":"11","key":"2475_CR27","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","volume":"19","author":"C De Smet","year":"1999","unstructured":"De Smet C, et al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 1999;19(11):7327\u201335.","journal-title":"Mol Cell Biol"},{"issue":"13","key":"2475_CR28","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1158\/1078-0432.CCR-11-0653","volume":"17","author":"S Bhan","year":"2011","unstructured":"Bhan S, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res. 2011;17(13):4267\u201376.","journal-title":"Clin Cancer Res"},{"key":"2475_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","volume":"67","author":"E Schooten","year":"2018","unstructured":"Schooten E, et al. MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev. 2018;67:54\u201362.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2475_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/ijc.2910630411","volume":"63","author":"H Inoue","year":"1995","unstructured":"Inoue H, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer. 1995;63(4):523\u20136.","journal-title":"Int J Cancer"},{"issue":"8","key":"2475_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.prp.2017.05.007","volume":"213","author":"Y Lian","year":"2017","unstructured":"Lian Y, et al. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients. Pathol\u2014Res Pract. 2017;213(8):943\u20138.","journal-title":"Pathol\u2014Res Pract"},{"key":"2475_CR32","doi-asserted-by":"publisher","first-page":"e14637","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637","volume":"35","author":"DJ Jonker","year":"2017","unstructured":"Jonker DJ, et al. Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. J Clin Oncol. 2017;35:e14637\u2013e14637.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2475_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2475_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/jclinpath-2016-203718","volume":"70","author":"M Sang","year":"2017","unstructured":"Sang M, et al. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. J Clin Pathol. 2017;70(6):533\u201340.","journal-title":"J Clin Pathol"},{"issue":"12","key":"2475_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/2326-6066.CIR-15-0266","volume":"4","author":"Y Ohue","year":"2016","unstructured":"Ohue Y, et al. Survival of lung adenocarcinoma patients predicted from expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells. Cancer Immunol Res. 2016;4(12):1049\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2475_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-9966-30-2","volume":"30","author":"J-X Zhou","year":"2011","unstructured":"Zhou J-X, et al. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res. 2011;30(1):2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2475_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.arcmed.2016.06.001","volume":"47","author":"M Sang","year":"2016","unstructured":"Sang M, et al. Prognostic significance of MAGE-A11 in esophageal squamous cell carcinoma and identification of related genes based on DNA microarray. Arch Med Res. 2016;47(3):151\u201361.","journal-title":"Arch Med Res"},{"issue":"1","key":"2475_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12967-024-04918-0","volume":"22","author":"RJ Seager","year":"2024","unstructured":"Seager RJ, et al. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer. J Transl Med. 2024;22(1):141.","journal-title":"J Transl Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02475-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:17:30Z","timestamp":1725283050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02475-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2475"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02475-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4499622\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sarbajit Mukherjee and all other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional review board at Roswell Park Comprehensive Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"227"}}